South Korea’s Celltrion Optimistic On June EMA Approval For Remicade Biosimilar
This article was originally published in PharmAsia News
Executive Summary
Johnson & Johnson may soon face more competition to Remicade from Celltrion’s biosimilar Remsima, with the South Korean company more optimistic about EMA approval following a positive response at one of the world’s largest rheumatology congresses.